Published in Vasc Health Risk Manag on April 08, 2009
Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism (2012) 1.08
Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. Vasc Health Risk Manag (2013) 0.84
Novel treatments for cardiovascular disease prevention. Cardiovasc Ther (2011) 0.75
Single-pill combinations: a therapeutic option or necessity for vascular risk treatment? J Drug Assess (2013) 0.75
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 14.01
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA (2005) 12.00
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med (2008) 10.03
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol (2003) 5.77
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA (2004) 5.25
Analyses of cancer data from three ezetimibe trials. N Engl J Med (2008) 3.44
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther (2006) 2.83
Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol (2005) 2.67
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA (1990) 2.36
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation (2008) 2.30
Safety considerations with niacin therapy. Am J Cardiol (2006) 2.30
An assessment of statin safety by muscle experts. Am J Cardiol (2006) 2.16
Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. Circulation (2008) 1.99
Safety of aggressive lipid management. J Am Coll Cardiol (2007) 1.87
Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J (2008) 1.80
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care (2002) 1.73
Is it time for a cardiovascular primary prevention trial in the elderly? Stroke (2006) 1.69
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin (2006) 1.53
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol (2008) 1.43
Predictors of carotid intima-media thickness progression in young adults: the Bogalusa Heart Study. Stroke (2007) 1.38
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol (2008) 1.25
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol (2007) 1.22
Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol (2008) 1.21
Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol (2006) 1.17
Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol (2004) 1.16
Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.15
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.14
Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther (2002) 1.13
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs (2008) 1.02
Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther (2007) 0.99
Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J Lipid Res (2008) 0.98
Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol (1997) 0.98
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract (2004) 0.94
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol (2005) 0.94
Low-Dose Aspirin and Ibuprofen Reduce the Cutaneous Reactions Following Niacin Administration. Am J Ther (1995) 0.90
Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos (2007) 0.89
Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther (2007) 0.87
Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol (2008) 0.84
Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab (2003) 0.83
Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol (2006) 0.82
The safety of niacin in the US Food and Drug Administration adverse event reporting database. Am J Cardiol (2008) 0.80
Should We Use PPAR Agonists to Reduce Cardiovascular Risk? PPAR Res (2008) 0.80
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther (2006) 0.78